Payment overview · 2025
General Payments
$597.43
29 reported records · 10 companies
Healthcare provider profile · identity verified
Harshad Patel
Allopathic & Osteopathic Physicians|Internal Medicine · RAINBOW CITY, AL · NPI 1093770018
Verified facts
What the public records show
CMS Open Payments records show Harshad Patel received $597.43 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $217.70 | 36.4% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $98.36 | 16.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.01 | 9.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.47 | 9.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.96 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.43 | 6.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.27 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.81 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.68 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.74 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $597.43 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $144.05 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $98.36 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.13 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.76 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.01 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.96 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 157 |
| Montelukast Sodium | Montelukast Sodium | 376 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 141 |
| Losartan Potassium | Losartan Potassium | 266 | 93 |
| Famotidine | Famotidine | 265 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 91 |
| Omeprazole | Omeprazole | 227 | 89 |
| Carvedilol | Carvedilol | 225 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 71 |
| Furosemide | Furosemide | 216 | 103 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 81 |
| Gabapentin | Gabapentin | 176 | 76 |
| Metformin Hcl | Metformin Hcl | 176 | 72 |
| Lisinopril | Lisinopril | 164 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 60 |
| Glimepiride | Glimepiride | 144 | 56 |
| Ropinirole Hcl | Ropinirole Hcl | 135 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 46 |
| Potassium Chloride | Potassium Chloride | 110 | 50 |
| Celecoxib | Celecoxib | 107 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 21 |
| Trazodone Hcl | Trazodone Hcl | 99 | 42 |
| Methocarbamol | Methocarbamol | 98 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 34 |
| Ezetimibe | Ezetimibe | 95 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 32 |
| Fenofibrate | Fenofibrate | 76 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 34 |
| Meloxicam | Meloxicam | 75 | 30 |
| Buspirone Hcl | Buspirone Hcl | 74 | 26 |
| Doxepin Hcl | Doxepin Hcl | 74 | 39 |
| Tramadol Hcl | Tramadol Hcl | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 35 |
| Clonidine Hcl | Clonidine Hcl | 68 | 31 |
| Ozempic | Semaglutide | 68 | 16 |
| Alendronate Sodium | Alendronate Sodium | 63 | 24 |
| Allopurinol | Allopurinol | 60 | 25 |
| Ondansetron Odt | Ondansetron | 60 | 28 |
| Simvastatin | Simvastatin | 60 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 26 |
| Eliquis | Apixaban | 58 | 20 |
| Sertraline Hcl | Sertraline Hcl | 58 | 25 |
| Alprazolam | Alprazolam | 55 | 23 |
| Mounjaro | Tirzepatide | 54 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 23 |
| Pregabalin | Pregabalin | 53 | 24 |
| Methylprednisolone | Methylprednisolone | 51 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Cefdinir | Cefdinir | 49 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 17 |
| Prednisone | Prednisone | 45 | 24 |
| Spironolactone | Spironolactone | 44 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 26 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | 14 |
| Baclofen | Baclofen | 38 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 13 |
| Donepezil Hcl | Donepezil Hcl | 35 | 17 |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 12 |
| Linzess | Linaclotide | 33 | 19 |
| Azithromycin | Azithromycin | 32 | 28 |
| Fluconazole | Fluconazole | 32 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 13 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Atenolol | Atenolol | 26 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 23 | 11 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Mirtazapine | Mirtazapine | 22 | 11 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Topiramate | Topiramate | 20 | 11 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Finasteride | Finasteride | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Risperidone | Risperidone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $597.43 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Kerendia, LINZESS, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error